video
With no curative therapies available, treatment for indolent systemic mastocytosis comes down to addressing symptoms, explains Sudipto Mukherjee, MD, PhD, MPH, of Cleveland Clinic. This begs the question: should patients with minimal symptoms be treated? (2:07)
Abnormal activation of basophils occurs in patients with indolent systemic mastocytosis, with enhanced responsiveness to a chemotactic factor derived from bacteria. Here’s what this finding—and others—might imply for future treatments.
video
"It's a lived experience," says Sudipto Mukherjee, MD, PhD, MPH, of Cleveland Clinic. Nearly every patient with systemic mastocytosis will be sensitive to something, and it's often hard to predict. (2:39)
An analysis of registry data concluded that hypersensitivity reactions in patients with mastocytosis are caused by exposure to certain triggers, including low tryptase levels and stings from certain insects. Here’s what else the team learned.
Investigators from the National Institutes of Health recently tackled the challenge of determining whether autoantibodies to type I interferon detected in the serum of patients with systemic mastocytosis are markers of disease severity.
Investigators from Walter Reed Military Medical Center assessed the impact of a standardized screening protocol for systemic mastocytosis.
These findings suggest that analyzing a panel of proteins in the blood could help differentiate between indolent and advanced forms of systemic mastocytosis, potentially leading to more precise diagnoses and personalized treatment.
